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ABSTRACT

LYMPHOCYTE PROTEOMICS FOR MONITORING
LONG TERM IMMUNE SYSTEM DYNAMICS

Michaela A. McCown
Department of Plant and Wildlife Sciences
Bachelor of Science

Time dependent change in lymphocytes provides a necessary background for
monitoring the development of Chronic Lymphocytic Leukemia from asymptomatic to
malignant. Several bulk proteomics studies characterize differences between tumor cells
and healthy B cells, yet the transition to symptomatic disease is not well understood. This
could be shown by a longitudinal study beginning with asymptomatic patients if the rare
tumor cells in early stages can be isolated from small volume blood draws and effectively
characterized with few cells, such as was done here using healthy B cells to provide a
baseline for such studies to discriminate routine fluctuation from pathogenic changes.
Lymphocyte proteomic data from two subjects and two collection days show that B
lymphocytes change significantly with time. Most proteins were identified broadly in cell
types, collection dates, and subjects. This study shows that the overall correlation
between B lymphocytes from the same subject a month apart is nearly as low as the
correlation between B and T lymphocytes, though time dependent changes to
differentially expressed proteins are not as extreme as the differences between B and T

cells. These results show that lymphocyte subtypes can be collected and monitored by
global proteomics to identify change over time. This could allow characterization of
circulating tumor cells from patients with Chronic Lymphocytic Leukemia to identify
variability in each stage and differential expression as the disease progresses.
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INTRODUCTION
Chronic Lymphocytic Leukemia (CLL) demonstrates cancer as a
microevolutionary process where change over time is vital to treatment. Mutations in B
cells lead first to a small circulating population of clonal B cells, then a growing
population of circulating tumor cells, and after a long presymptomatic phase the cancer
becomes malignant.1 The disease is often discovered when a complete blood count
assay reports abnormally high lymphocyte counts as part of a routine checkup.
Following diagnosis, the disease is observed during a long asymptomatic period in
which treatment has either shown no benefit or has yet to be demonstrated sufficiently
for broad use, though several therapies are approaching the possibility of early
treatment.2 Once treatment is necessary, there are three common options—ibrutinib,
acalabrutinib, or venetoclax and obinutuzumab—that manage the disease in spite of
their side effects.3 Resistance is often acquired to these treatments and, though more
guided control may ameliorate the effects, additional biomarkers and novel treatments
are needed.4
Many studies show characteristics of CLL tumor cells in contrast with healthy
lymphocytes using global proteomics.5–9 Proteomics can identify complex pathways, as
opposed to isolated proteins, that are differentially expressed in diseased samples. This
is particularly advantageous in the complex interactions in cancer, provided high
accuracy and careful experimental design.10 Recent proteomic research has made
considerable progress understanding CLL. Effects of most established prognostic
marker, IGHV mutation status, are explained using advancing global proteomics
techniques.6 Proteomic distinctions between B cells from elderly subjects and B cells
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from young donors indicate that CLL cells exaggerate characteristics of aging. 8 Further
analysis shows that a number of the misregulated pathways are targeted by existing
therapeutics, which could be similarly beneficial in treating CLL. 7 Each study reveals
more about the pathogenicity of CLL and leads towards more effective treatment
options.5
While the differences between circulating CLL tumor and healthy B
lymphocyte protein expression profiles are well characterized, 6,8 the changes that
accompany the transition to malignance are not. Regulatory changes in disease give a
greater level of understanding to the mechanism of disease and, by revealing those
mechanisms, suggest avenues for potential treatment options. However, many studies
are unable to show how much the expression changes throughout the disease or even in
healthy tissues. For any disease, understanding changes across the natural history
provides important insight for developing improved treatment options and identifying
prognostic markers. CLL’s asymptomatic stage provides an opportunity to collect
samples prior to and as the tumor cells become malignant. Before those changes can be
monitored, an analysis must be established that can characterize rare cell types like
circulating tumor cells in early CLL with a minimally invasive sample collection, such
as small volume blood draws, that will allow frequent sampling. Likewise, analysis of
CLL’s malignant changes requires an understanding of normal variability in B
lymphocytes.
This study shows proteome changes in healthy individuals under normal
conditions by comparing lymphocytes collected one month apart. This demonstrates an
effective method of small sample analysis in select populations of blood cells. Samples
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from two subjects were collected one month apart, sorted into B and T cells (Figure 1).
Samples were sorted into B and T cells provide the level of distinction between the two
lymphocyte subpopulations as context for the variability between time points. These
cells were analyzed by mass spectrometry and
compared to reveal proteome level differences.
Over one month, the B cell proteome changes
less than the amount that proteins differ
between B and T cells. This provides a
background to what level of change is aberrant
and what variation represents disease, and
more fundamentally shows the flexibility in
phenotype of immune cells in healthy
individuals.

METHODS

Figure 1. Experimental Design. As
shown, blood was drawn from each
of two subjects twice, one month
apart in June and July. Each sample
was processed identically and
sorted into 145 cell samples for
proteomic analysis by mass
spectrometry to show the variation
across a short period of time.

Lymphocyte Collection
At each sampling time, whole blood samples were collected from the Student
Health Center (IRB Authorization X19045: Understanding the Progression of Chronic
Lymphocytic Leukemia). Samples were from two healthy adult male volunteers.
Samples were kept on ice for transport and prior to processing. These samples were
collected in June and July of 2020, thirty days apart. Each time, one 4ml EDTA tube of
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whole blood was taken for lymphocyte isolation. Additional blood was sent to LabCorp
for two clinical tests, a complete blood count and comprehensive metabolic panel.
White blood cells were isolated by lysing the red blood cells and pelleting the
intact cells. Cells were processed in triplicate from 200 μl whole blood. Along with
sample replicates, four single color controls were prepared for FACS sorting: cells
only, APC-positive, FITC-positive, and PI-positive. 100 μl whole blood was used for
each control. Propidium iodide (PI) marks dead or dying cells by staining exposed
DNA, so dead cells were necessary for the PI-positive control and month-old
refrigerated blood was used. Each sample was mixed with 4ml of red blood cell lysis
buffer in 5 ml falcon tubes and incubated for 5 minutes at room temperature. Debris
was separated from intact white blood cells by centrifugation at 250 g for 5 minutes and
the supernatant was decanted.
Lymphocytes were marked using fluorescent immunostaining. T lymphocytes
and B lymphocytes were marked using CD3 anti-human FITC and CD19 anti-human
APC (BioLegend), respectively. Cells were resuspended in 100 μl of phosphate buffer
saline (PBS) with 5 μl of each immunostain. 10 μl PI was added to samples and the
appropriate control tube to allow for the exclusion of dead cells. Samples were
incubated for 20 minutes in the dark at room temperature. Excess dye was removed by
washing with 2 ml PBS, then removed by centrifuging at 250 g for 5 minutes and
decanting the supernatant. The cells were resuspended in 300 μl, bringing the cell
suspension to an appropriate concentration for FACS sorting. This procedure is
available on protocols.io.11 Cells were then FACS sorted to samples of 145 cells in 384
well plates that were prewashed with water, mobile phase A, 0.01% n-dodecyl β-D-
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maltoside (DDM) in stages and prefilled with 4 μl to minimize cell damage from
sorting.

Protein Quantification by Mass Spectrometry
Samples were analyzed using standard global proteomics for low input samples.
Protein was extracted prepared using automated digestion and nanoLC-MS/MS as
described by Liang et al.12 Cells were sonicated for 5 minutes and centrifuged at 1500
rpm for 1 minute to collect. The OT-2 liquid handler (Opentrons, Brooklyn, NY)
carried out further sample processing as reported previously. 12 In brief, the liquid
handler added the following: 1 μl dithiothreitol, then 2 μl every 15 minutes during a 1
hour incubation at 70 ℃, 1 μl iodoacetamide prior to a 30 minute incubation at 25℃, 1
μl lys-C prior to a 3 hour incubation at 37℃, 1 μl trypsin, 2 μl water every 3 hours
during a 12 hour incubation at 37℃, 1 μl water and 1 μl 5% formic acid prior to a 1
hour incubation at 25℃. At that time, samples were stored at -20℃ till thawing for
nanoLC-MS/MS.
Samples were run from each cell type for each subject in five replicates on an
Orbitrap Exploris 480 (Thermo Fisher) mass spectrometer using a Nanospray Flex ion
source at 2.0 kV. Runs used a maximum injection time of 250 ms and an exclusion
duration of 90s. For additional settings, see the methodological details explained in
reference 12. The raw files will be made available on a public server when submitted
for publication. Raw mass spectrometry files were processed using the FragPipe
interface with MSFragger13 and IonQuant14 using default settings. Match Between Runs
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was not used. False discovery rates are 0.01. The database search was conducted with a
UniProt FASTA file (Swiss-Prot, reviewed, and downloaded July 2020).

Relationship Analysis
Specific analyses were conducted in Python using Jupyter Notebooks. My code
can be found on GitHub at github.com/PayneLab/Lymphocytes2 following a standard
dissemination pattern.15 Two additional tools were used for figure creation; Figure 1
was created with BioRender.com and Figure 2 using InteractiVenn.net with output from
a Jupyter Notebook. The quantification tables were read in as Pandas dataframes, then
normalized by log 2 transformation. Because batch effects will shift the signal intensity
between runs, each run was adjusted by its median value to create a normalized dataset
of relative intensities centered at zero. Identifications by sample are counted by the
number of protein groups with a non-null value. Gene set enrichment analysis 16,17 was
done using the cell type classifier ProteomicsDB 18 to verify these proteins as
lymphocyte-representative expressions. Proteins were filtered by cell type for those that
are present in at least half the samples. Spearman correlation coefficients were
calculated to show reproducibility within a cell type. To better display the change
between B lymphocytes collected at each time, the fold change was calculated for each
protein and graphed on a log 2 scale. These figures were created using Seaborn and
pyplot. Significance of relationships was determined by t-test for independent samples
with Bonferroni correction.
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RESULTS
Global proteomics of lymphocyte samples collected one month apart
demonstrate time dependent change. Comparison of B and T lymphocytes provide
context for the magnitude of that change and will allow long term analysis of variation
during disease development. Proteomic data was analyzed from two subjects at each
time point in five replicates for a total of forty datasets.

Identifications
FragPipe identifies a total of 2426 unique proteins from global
proteomics analysis in these datasets. 1080-1607 proteins are identified in each sample.
Confirming the effectiveness of this coverage, gene set enrichment analysis by tissue
type shows that these proteins are highly similar to lymphoblastoid cells (Adjusted p
value = 2.103470e-08). In
analyzing reproducibility,
proteins used are
consistently identified in at
least half the replicates. Of
the proteins consistent in
any group, most are shared
across groups for a common
set of 1056 proteins (Figure
Figure 2. Core Identifications. The number of proteins
identified in half the replicates from each group of
samples.

2). The next largest regions
are in samples from the
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second time point (165 were only in July B cells and 109 in both cell types in July),
which has more identifications overall. By contrast with the central overlap, relatively
few proteins are uniquely identified in any category. The proteins not identified may
represent insufficient sample or lower instrument sensitivity as well as genuine
absence. This indicates a large core set of proteins can be accurately compared for
differential expression.

Reproducibility
Both cell types have high technical reproducibility as shown by an average
Spearman correlation coefficient of 0.91 between sample replicates. This provides a
baseline for variation between replicates. When comparing all samples of a cell type,
combining both time points and subjects, reproducibility drops to 0.87 for B cells and
0.89 for T cells. Correlation is lowest between samples of different cell types at an
average correlation of 0.85. This data distinguishes the subpopulations of B and T cells,
while reflecting the similarity between the two types of lymphocytes.

Time Dependent Change
The Spearman correlation coefficients show the extent to which comprehensive
patterns in protein expression persist across samples. B lymphocytes from the first
sampling correlate with corresponding samples from the second date at a coefficient of
0.88. This is more variable than technical replicates (p=1.95e-4), and near the
variability between B and T lymphocytes from the same sampling time (p=.06)
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showing that protein
expression changes in one
month is to a similar extent
as defining two cell types
(Figure 3). More data is
necessary to show whether
the time comparison
correlation is significantly
higher than the cell type
comparison. The range of
correlation is broad,
reaching lower than cross
cell types and nearly as
high as technical replicates.

Figure 3. Magnitude of Time Dependent Change.
Correlation coefficients are plotted for three key
comparisons: technical replicates of B cells from day 0,
B cells from day 0 compared to day 30, and B cells
compared to T cells from the same time (day 0). Each
subject’s data was compared separately.

Specific Expression
Most proteins regardless of sample type show only moderate change, with a
small differentiating set of proteins. The variable proteins across time are fewer and
have milder changes than between cell types. As well as by overall correlation patterns,
time dependent change is shown in terms of differentially expressed proteins. At
p<0.05, 67 proteins from B lymphocytes in Subject 1 change significantly in abundance
between sampling times (Figure 4a). For comparison, 105 proteins are significantly

9

different in abundance using Subject 1's first sampling between B and T lymphocytes
(Figure 4b). Both comparisons show that the majority of proteins are similarly
expressed while a subset of proteins is not. The most extreme time dependent changes
are lower in both magnitude and significance than the extreme changes between cell
types (Figure 4).
a)

b)

Figure 4. Differential Expression Profile. Variably expressed proteins from day 1 to
30 in Subject 1 B cells (a) and between B and T cells from Subject 1 at day 1 (b) are
identified using fold change against P value.

DISCUSSION
I present a comparison of repeated sampling of global lymphocyte proteomics in
the context of cell type variability. This characterization of short-term variation will aid
in discriminating routine fluctuation from pathogenic changes and indicates that small
sample analysis yields sufficient coverage depth for time dependent changes. A
population across time points has variability near that of the different cell types. B
lymphocytes show more slightly lower correlation and higher expression shifts than do
T lymphocytes. Additional research is necessary to show to what extent the adaptation
10

influences expression changes, yet as B cells give rise to a variety of clonal populations
it is unsurprising to see more variability.
At one month apart, these data show routine variation and seasonal effects are
unlikely. Seasonal effects do change health metrics on blood and disease frequency. 19,20
Another example of seasonal change is shown in proteins, metabolites, and clinical
tests on blood samples.21 Blood pressure also varies across seasons, correlated with
outdoor temperature.22 This study shows variation from two points in the summer with
similar weather. Additional data will show to what extent the patterns shown in higher
level blood measurements are mirrored in lymphocyte proteomics. Long-term sampling
and characterization of key immune cells will allow us to better understand immune
system dynamics.
The ability to characterize such small samples is necessary for longitudinal CLL
research. Small sample proteomics are rapidly advancing, yet lymphocytes are still an
unusual application.23 For common cell types or intact tissues, better results may be
obtained from bulk analysis such as Mayer’s 20 μg of protein extract identifying 6,945
proteins8 or Johnston’s 100 μg of cell lysate for 8694 proteins, 7 each of which would
require millions of cells.24 However, the reduction in number of proteins identified is
justified by the diverse applications that will allow only restricted sample size due to
collection of rare cell types. Limited blood draws do not yield millions of rare cells for
microgram samples as required for bulk proteomics, but could give a few hundred.
These few cells would be effectively characterized by small scale assays like this
lymphocyte characterization.
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In conclusion, time dependent change in lymphocytes is nearly as high as the
variation between lymphocyte subpopulations. This baseline indicates changes that
occur in healthy subjects’ B lymphocytes over time. The methods demonstrated here
effectively characterize the proteome from 145-cell samples sorted by surface antigens
and will allow longitudinal analysis of even rare cell types. The baseline variability and
the monitoring methods will allow analysis of lymphocyte population changes during
the course of disease.
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